



RepliCel™

Using Cells for Healing


OTCQB: REPCF | TSXV: RP | FRA:P6P2

COMPANY PROFILE Q4 2018

A Revolution in Sports Medicine and Aesthetics.

We are a regenerative medicine company with innovative cell therapy technology providing unparalleled skin rejuvenation, tendon regeneration, and hair regrowth.

Three applications, two biologics, one game-changing delivery platform



RCI-02 PATENTED DERMAL INJECTION DEVICE

The RCI-02 dermal injector is designed to deliver cells, dermal fillers, drug and biologics.

- Digital controls program for depth, volume, rate of dispersion
- Provides exact repeatable dispersion across 3 dimensions
- Removes human variability
- Built-in Peltier element reduces need for anesthetics
- Near-term commercial launch



Poised for growth and momentum

Potential to Revolutionize Sports Medicine and Aesthetics

This innovative cell therapy technology has the potential to revolutionize two large consumer-pay markets where few solutions exist.

The Only Regenerative Medicine Company Using Hair Follicle Cell Therapy

We are the only Company using cells derived from hair follicles to potentially heal damaged skin and tendon tissue—offering hope for people with conditions beyond repair.

Multiple Assets Addressing Conditions With Unmet Need

Multi-product portfolio diversifies risk over several programs in two different markets.

Near-Term Commercial Launch And Revenue Catalysts

Patented injection device could generate sales and revenues as early as 2019 in Europe and Hong Kong. Hair regrowth product could be launched in Japanese market as early as 2019.

Multiple Assets Across Large Markets with Key Partnership in Place

Positive phase I clinical data and dermal injector prototypes focused on skin, tendon and hair health (all large markets).

Management Is Commercially-Focused And Strategic

Focus is on leveraging partnership programs and preparing for commercial product launch.

Capital Structure (as at Nov, 2018)

Current market cap. (approx.)	~\$12M
Total money raised through equity to-date	~\$27M
Total revenue to-date (including initial Shiseido licensing payment)	\$3.8M
Current Monthly Burn Rate	~\$180,000
Shares Issued and Outstanding (Basic/FD)	26.8M / 33.4M
Inside Ownership	~21%

Board and Management Team

David Hall Chairman	R. Lee Buckler, B. Ed, LLB President, CEO & Director
Geoff MacKay Director	Dr. Rolf Hoffman, MD Chief Medical Officer
Peter Lewis, CA Director	Dr. Kevin McElwee, PhD Chief Scientific Officer
Lee Buckler Director	Simon Ma CA Chief Financial Officer
Hugh Rogers Director	Petra Goessens-Rueck, DVM Head of Clinical and Regulatory Affairs